drugset / Trial / NCT02367690

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

NCT02367690

Phase 1/2 Withdrawn Karyopharm Therapeutics Inc
RandomizedParallel-groupSingle-blindTreatment

Summary

Patients with eligible diabetic foot ulcers will be screened, treated, and followed for complete ulcer closure. This is a randomized trial. All patients will receive standard-of-care treatment. Additionally, some patients will receive treatment with topical Selinexor gel and some will receive topical placebo gel.

Timeline

Start
2015-01
Primary completion
2015-05
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Selinexor Other / unclassified 10 unknown Topical
Subject Selinexor Other / unclassified 30 unknown Topical
Subject Selinexor Other / unclassified 70 unknown Topical

Indications